Nanostructured lipid carriers: A novel platform for chemotherapeutics

Current Drug Delivery

Volumn 13, Issue 1, 2016, Pages 4-26

  Rizwanullah, Md ^a   Ahmad, Javed ^a   Amin, Saima ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Multidrug resistance; Nanostructured lipid carriers; P glycoprotein; Receptors; Targeting; Theranostics; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; CRYOPROTECTIVE AGENT; DRUG PRESERVATIVE; EXCIPIENT; LIPID; LIQUID LIPID NANOPARTICLE; NANOCARRIER; NANOPARTICLE; SOLID LIPID NANOPARTICLE; SURFACTANT; UNCLASSIFIED DRUG; DRUG CARRIER; NANOMATERIAL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CANCER RESISTANCE; CANCER THERAPY; CRYSTALLIZATION; DISPERSION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; GENE TARGETING; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LIPOPHILICITY; MULTIDRUG RESISTANCE; NANOSTRUCTURED LIPID CARRIER; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; STRUCTURE ANALYSIS; SURFACE PROPERTY; TEMPERATURE; THERANOSTIC NANOMEDICINE; ZETA POTENTIAL; ANIMAL; CHEMISTRY; NEOPLASMS; SOLUBILITY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; LIPIDS; NANOPARTICLES; NANOSTRUCTURES; NEOPLASMS; SOLUBILITY;

EID: 84964034025     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/1567201812666150817124133     Document Type: Article

References (211)

1. WHO: Cancer. http://www.who.int/mediacentre/factsheets/fs297/en/ (Accessed 29 September 29, 2014).
2. Bhosle, J.; Hall, G. Principles of cancer treatment by chemotherapy. Surgery, 2009, 27(4), 173-177.
3. Boyle, P.; Levin, B. In: World Cancer Report. International Agency for Research on Cancer, Lyon, France, 2008; pp. 62-67
4. Feng, S.S.; Chien, S. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem. Eng. Sci., 2003, 58(18), 4087-4114
5. Davis, M.E.; Chen, Z.; Shin, D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov., 2008, 7(9), 771-82
6. Arias, J.L.; Galllardo, V.; Gomez-Lopera, S.A.; Plaza, R.C.; Delgado, A.V. Synthesis and characterization of poly(ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. J. Control. Release, 2001, 77(3), 309-321
7. Joshi, M.D.; Muller, R.H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm., 2009, 71(12), 161-172
8. Muller, R.H.; Mader, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50(1), 161-177
9. Jores, K.; Mehnert, W.; Mader, K. Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: a nuclear magnetic resonance and electron spin resonance study. Pharm. Res., 2003, 20(8), 1274-1283
10. Muller, R.H.; Radtke, M.; Wissing, S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm., 2002, 242(1-2), 121-128
11. Shidhaye, S.S.; Vaidya, R.; Sutar, S.; Patwardhan, A.; Kadam, V.J. Solid lipid nanoparticles and nanostructured lipid carriersinnovative generations of solid lipid carriers. Curr. Drug Deliv., 2008, 5(4), 324-31
12. Souto, E.B.; Muller, R.H. In: Drug delivery; Schafer-Korting, M, Ed.; Springer Berlin Heidelberg: FU Berlin, 2010; Vol. 197, pp 115-141
13. Jannin, V.; Musakhanian, J.; Marchaud, D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv. Drug Deliv. Rev., 2008, 60(6), 734-746
14. Christie, W.W. High-Performance Liquid Chromatography and Lipids: A Practical Guide. Pergamon Books, Oxford, New York, 1987
15. Jenning, V.; Thunemann, A.F.; Gohla, S.H. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm., 2000, 199(2), 167-177
16. Constantinides, P.P.; Tustian, A.; Kessler, D.R. Tocol emulsions for drug solubilization and parenteral delivery. Adv. Drug Deliv. Rev., 2004, 56(9), 1243-1255
17. Ahmad, J.; Kohli, K.; Mir, S.R.; Amin, S. Lipid based nanocarriers for oral delivery of cancer chemotherapeutics: An insight in the intestinal lymphatic transport. Drug Deliv. Lett., 2013, 3, 38-46
18. Porter, C.J.; Natalie, L.T.; William, N.C. Lipids and lipid based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov., 2007, 6(3), 231-248
19. Neupane, Y.R.; Srivastava, M.; Ahmad, N.; Kumar, N.; Bhatnagar, A.; Kohli, K. Lipid based nanocarrier system for the potential oral delivery of Decitabine: Formulation design, characterization, ex vivo, and in vivo assessment. Int. J. Pharm., 2014, 477(1-2), 601-612
20. Elnaggar, Y.S.; El-Massik, M.A.; Abdallah, O.Y. Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipid nanoparticles. Int. J. Nanomedicine, 2011, 6, 3195-3205
21. Seyfoddin, A.; Al-Kassas, R. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev. Ind. Pharm., 2013, 39(4), 508-519
22. Gadhe, A.P.; Pokharkar, V. Montelukast-loaded d lipid carriers: Part I. Oral bioavailability improvement. Eur. J. Pharm. Biopharm., 2014, 88(1), 160-168
23. Mendes, A.I.; Silva, A.C.; Catita, J.A.; Cerqueira, F.; Gabriel, C.; Lopes, C.M. Miconazole-loaded nanostructured lipid carriers (NLC) for local delivery to the oral mucosa: Improving antifungal activity. Colloids Surf. B. Biointerfaces, 2013, 111, 755-763
24. Joshi, M.; Patravale, V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int. J. Pharm., 2008, 346(1-2), 124-132
25. Negi, L.M.; Talegaonkar, S.; Jaggi, M.; Verma, A.K.; Verma, R.; Dobhal, S.; Kumar, V. Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part II. In vivo biodistribution, pharmacodynamic and hematological toxicity studies. Colloids Surf. B. Biointerfaces, 2014, 123, 610-615
26. Carbone, C.; Campisi, A.; Musumeci, T.; Raciti, G.; Bonfanti, R.; Puglisi, G. FA-loaded lipid drug delivery systems: Preparation, characterization and biological studies. Eur. J. Pharm. Sci., 2014, 52, 12-20
27. Loo, C.H.; Basri, M.; Ismail, R.; Lau, H.; Tejo, B.A.; Kanthimathi, M.S.; Hassan, H.A.; Choo, Y.M. Effect of compositions in nanostructured lipid carriers (NLC) on skin hydration and occlusion. Int. J. Nanomedicine, 2013, 8, 13-22
28. Souza, L.G.; Silva, E.J.; Martins, A.L.; Mota, M.F.; Braga, R.C.; Lima, E.M.; Valadares, M.C.; Taveira, S.F.; Marreto, R.N. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur. J. Pharm. Biopharm., 2011, 79(1), 189-196
29. Aditya, N.P.; Shim, M.; Lee, I.; Lee, Y.J.; Im, M.H.; Ko, S. Curcumin and Genistein co-loaded nanostructured lipid carriers: in vitro digestion and antiprostate cancer activity. J. Agric. Food Chem., 2013, 61(8), 1878-1883
30. Patel, A.R.; Chougule, M.B.; Ian, T.; Patlolla, R.; Guangdi, W.; Singh, M. Efficacy of aerosolized Celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with Docetaxel. Pharm Res., 2013, 30(5), 1435-1446
31. Abdelbary, G.; Haider, M. In vitro characterization and growth inhibition effect of nanostructured lipid carriers for controlled delivery of methotrexate. Pharm. Dev. Technol., 2011, 18(5), 1159-1168
32. Lin, Y.K.; Huang, Z.R.; Zhuo, R.Z.; Fang, J.Y. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int. J. Nanomedicine, 2010, 5, 117-128
33. Kumbhar, D.D.; Pokharkar, V.B. Engineering of a nanostructured lipid carrier for the poorly water-soluble drug, bicalutamide: Physicochemical investigations. Colloids Surf. A. Physicochem. Eng. Asp., 2013, 416, 32-42
34. Zhang, T.; Chen, J.; Zhang, Y.; Shen, Q.; Pan, W. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur. J. Pharm. Sci., 2011, 43(3), 174-179
35. How, C.W.; Rasedee, A.; Manickam, S.; Rosli, R. Tamoxifenloaded nanostructured lipid carrier as a drug delivery system: characterization, stability assessment and cytotoxicity. Colloids Surf. B. Biointerfaces, 2013, 112, 393-399
36. Su, Z.; Niu, J.; Xiao, Y.; Ping, Q.; Sun, M.; Huang, A.; You, W.; Sang, X.; Yuan, D. Effect of octreotide polyethylene glycol (100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with Hydroxycamptothecine. Mol. Pharm., 2011, 8(5), 1641-1651
37. Li, F.; Weng, Y.; Wang, L.; He, H.; Yang, J.; Tang, X. The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers. Int. J. Pharm., 2010, 393(1-2), 203-211
38. Shi, F.; Yang, G.; Ren, J.; Guo, T.; Du, Y.; Feng, N. Formulation design, preparation, and in vitro and in vivo characterizations of β-elemene-loaded nanostructured lipid carriers. Int. J. Nanomedicine, 2013, 8, 2533-2541
39. Shete, H.K.; Selkar, N.; Vanage, G.R.; Patravale, V.B. Tamoxifen nanostructured lipid carriers: Enhanced in vivo antitumor efficacy with reduced adverse drug effects. Int. J. Pharm., 2014, 468(1-2), 1-14
40. Zhang, W.; Li, X.; Ye, T.; Chen, F.; Sun, X.; Kong, J.; Yang, X.; Pan, W.; Li, S. Design, characterization, and in vitro cellular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology. Int. J. Pharm., 2014, 454(1), 354-366
41. Khalil, R.M.; Abd-Elbary, A.; Kassem, M.A.; Ghorab, M.M.; Basha, M. Nanostructured lipid carriers (NLC) versus solid lipid nanoparticles (SLNs) for topical delivery of meloxicam. Pharm. Dev. Technol., 2014, 19(3), 304-314
42. Khajavinia, A.; Varshosaz, J.; Dehkordi, A.J. Targeting etoposide to acute myelogenous leukaemia cells using nanostructured lipid carriers coated with transferrin. Nanotechnology, 2012, 23(40), 405101
43. Vitorino, C.; Almeida, J.; Gonçalves, L.M.; Almeida, A.J.; Sousa, J.J.; Pais, A.A. Co-encapsulating nanostructured lipid carriers for transdermal application: From experimental design to the molecular detail. J. Control. Release, 2013, 167(3), 301-314
44. Zhao, C.; Liu, Y.; Fan, T.; Zhou, D.; Yang, Y.; Jin, Y.; Zhang, Z.; Huang, Y. A novel strategy for encapsulating poorly soluble drug into nanostructured lipid carriers for intravenous administration. Pharm. Dev. Technol., 2012, 17(4), 443-456
45. Sun, M.; Nie, S.; Pan, X.; Zhang, R.; Fan, Z.; Wang, S. Quercetinnanostructured lipid carriers: Characteristics and anti-breast cancer activities in vitro. Colloids Surf. B. Biointerfaces, 2014, 113, 15-24
46. Li, X.; Nie, S.F.; Kong, J.; Li, N.; Ju, C.Y.; Pan, W.S. A controlledrelease ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int. J. Pharm., 2008, 363(1-2), 177-182
47. Attwood, D.; Florence, A.T. Surfactant systems: their chemistry, pharmacy and biology. Chapman and Hall, London, 1983; pp. 794
48. Strickley, R. G. In: Oral lipid-based formulations: enhancing the bioavailability of poorly water soluble drugs; Hauss, D.J. Ed.; Informa Healthcare, Inc., New York, 2007, pp. 1-31
49. Schafer-Korting, M.; Mehnert, W.; Korting, H.C. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv. Drug Deliv. Rev., 2007, 59(6), 427-443
50. Rosenblatt, K.M.; Bunjes, H. Poly(vinyl alcohol) as emulsifier stabilizes solid triglyceride drug carrier nanoparticles in the α-modification. Mol. Pharm., 2009, 6(1), 105-120
51. Gu, X.; Zhang, W.; Liu, J.; Shaw, J.P.; Shen, Y.; Xu, Y.; Lu, H.; Wu, Z. Preparation and characterization of a Lovastatin-loaded protein-free nanostructured lipid carrier resembling high-density lipoprotein and evaluation of its targeting to foam cells. AAPS Pharm. Sci. Tech., 2011, 12(4), 1200-1208
52. Mehnert, W.; Mader, K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev., 2001, 47(2-3), 165-196
53. Zhang, X.; Pan W.; Gan L.; Zhu, C.; Gan, Y.; Nie, S. Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying. Chem. Pharm. Bull., 2008, 56(12), 1645-1650
54. Zhang, X.; Gan, Y.; Gan, L.; Nie, S.; Pan, W. PEGylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: an efficient carrier with enhanced anti-tumour effects against lung cancer. J. Pharm. Pharmacol., 2008, 60(8), 1077-1087
55. Zhang, P.; Ling, G.; Pan, X.; Sun, J.; Zhang, T.; Pu, X.; Yin, S.; He, Z. Novel nanostructured lipid-dextran sulfate hybrid carriers overcome tumor multidrug resistance of mitoxantrone hydrochloride. Nanomedicine, 2012, 8(2), 185-193
56. Chen, Y.; Yang, X.; Zhao, L.; Almasy, L.; Garamus, V.M.; Willumeit, R.; Zou, A. Preparation and characterization of a nanostructured lipid carrier for a poorly soluble drug. Colloids Surf. A. Physicochem. Eng. Asp., 2014, 455, 36-43
57. Carbone, C.; Campisi, A.; Manno, D.; Serra, A.; Spatuzza, M.; Musumeci, T.; Bonfanti, R.; Puglisi, G. The critical role of didodecyldimethylammonium bromide on physico-chemical, technological and biological properties of NLC. Colloids Surf. B. Biointerfaces, 2014, 121, 1-10
58. Mitri, K.; Shegokar, R.; Gohla, S.; Anselmi, C.; Muller, R.H. Lipid nanocarriers for dermal delivery of lutein: Preparation, characterization, stability and performance. Int. J. Pharm., 2011, 414(1-2), 267-275
59. Chen, C.C.; Tsai, T.H.; Huang, Z.R.; Fang, J.Y. Effects of lipophilic emulsifiers on the oral administration of Lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur. J. Pharm. Biopharm., 2010, 74(3), 474-482
60. Pereda, J.; Ferragut, V.; Quevedo, J.M.; Guamis, B.; Trujillo, A.J. Effects of ultra-high pressure homogenization on microbial and physicochemical shelf life of milk. J. Dairy Sci., 2007, 90(3), 1081-1093
61. Lucks, J.S.; Müller, R.H. Medication vehicles made of solid lipid particles (solid lipid Nanospheres SLN). C.A 2,119,253 A1, 1991
62. Diels, A.M.; Michiels, C.W. High-pressure homogenization as a non thermal technique for the inactivation of microorganisms. Crit. Rev. Microbiol., 2006, 32(4), 201-216
63. Hommoss, A. Preservative system development for argan oil-loaded nanostructured lipid carriers. Pharmazie, 2011, 66(3), 187-191
64. Obeidat, W.M.; Schwabe, K.; Müller, R.H.; Keck, C.M. Preservation of nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm., 2010, 76(1), 56-67
65. Gibson, L. In: Oral lipid-based formulations: enhancing the bioavailability of poorly water soluble drugs; Hauss, D. J. Ed.; Informa Healthcare, Inc., New York, 2007; pp. 33-61
66. Teeranachaideekul, V.; Müller, R.H.; Junyaprasert, V.B. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC) effects of formulation parameters on physicochemical stability. Int. J. Pharm., 2007, 340(1-2), 198-206
67. Fang, M.; Jin, Y.; Bao, W.; Gao, H.; Xu, M.; Wang, D.; Wang, X.; Yao, P.; Liu, L. In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration. Int. J. Nanomedicine, 2012, 7, 5395-5404
68. Hu, F.Q.; Jiang, S.P.; Du, Y.Z.; Yuan, H.; Ye, Y.Q.; Zeng, S. Preparation and characteristics of monostearin nanostructured lipid carriers. Int. J. Pharm., 2006, 314(1), 314, 83-89
69. Varshosaz, J.; Eskandari, S.; Tabbakhian, M. Freeze-drying of nanostructure lipid carriers by different carbohydrate polymers used as cryoprotectants. Carbohydr. Polym., 2012, 88(4), 1157-1163
70. Emami, J.; Rezazadeh, M. Varshosaz, J.; Tabbakhian, M; Aslani, A. Formulation of LDL targeted nanostructured lipid carriers loaded with paclitaxel: A detailed study of preparation, freeze drying condition, and in vitro cytotoxicity. J. Nano Mat. 2012, 12, 1-10, Doi: 10.1155/2012/358782
71. Jia, L.; Zhang, D.; Li, Z.; Duan, C.; Wang, Y.; Feng, F.; Wang, F.; Liu, Y.; Zhang, Q. Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies. Colloids Surf. B. Biointerfaces, 2010, 80, 213-218
72. Li, X.; Wang, D.; Zhang, J.; Pan, W. Preparation and pharmacokinetics of docetaxel based on nanostructured lipid carriers. J. Pharm. Pharmacol., 2009, 61(11), 1485-1492
73. Xia, Q.; Kong, R. Freeze-drying and characterization of vitamin A palmitate-loaded nanostructured lipid carriers (NLC). Mater. Sci. Forum, 2011, 694, 365-369
74. Fang, C.L.; Al-Suwayeh, S.A.; Fang, J.Y. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat. Nanotechnol., 2013, 7, 41-55
75. Jores, K.; Haberland, A.; Wartewig, S.; Mader, K.; Mehnert, W. Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorometry and Raman spectroscopy. Pharm. Res., 2005, 22(11), 1887-1897
76. Bunjes, H.; Westesen, K.; Koch, M.H. Crystallization tendency and polymorphic transition in triglyceride nanoparticles. Int. J. Pharm., 1996, 129(1-2), 159-173
77. Muller, R.H.; Radtke, M.; Wissing, S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev., 2002, 54, 131-155
78. Radtke, M.; Muller, R.H. Nanostructured lipid carriers: the new generation of lipid drug carriers. New Drugs, 2001, 2, 48-52
79. Stecova, J.; Mehnert, W.; Blaschke, T.; Kleuser, B.; Sivaramakrishnan, R.; Zouboulis, C. C.; Seltmann, H.; Korting, H.C.; Kramer, K.D.; Schäfer-Korting, M. Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm, Res., 2007, 24(5), 991-1000
80. Huang, Z.R.; Hua, S.C.; Yang, Y.L.; Fang, J.Y. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta. Pharmacol. Sin., 2008, 29(9), 1094-1102
81. Ruktanonchai, U.; Bejrapha, P.; Sakulkhu, U.; Opanasopit, P.; Bunyapraphatsara, N.; Junyaprasert, V.; Puttipipatkhachorn, S. Physicochemical characteristics, cytotoxicity, and antioxidant activity of three lipid nanoparticulate formulations of alpha-lipoic acid. AAPS Pharm. Sci. Tech., 2009, 10(1), 227-234
82. Das, S.; Chaudhary, A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS Pharm. Sci. Tech., 2011, 12(1), 62-76
83. Gasco, M.R. Method for producing solid lipid microspheres having a narrow size distribution. U.S. Patent 5,250,236 1993
84. Igartua, M.; Saulnier, P.; Heurtault, B.; Pech, B.; Proust, J.E.; Pedraz, J.L.; Benoit, J.P. Development and characterization of solid lipid nanoparticles loaded with magnetite. Int. J. Pharm., 2002, 233(1-2), 149-157
85. Bondi, M.L.; Azzolina, A.; Craparo, E.F.; Lampiasi, N.; Capuano, G.; Giammona, G.; Cervello, M. Novel cationic solid lipid nanoparticles as non-viral vectors for gene delivery. J. Drug Target., 2007, 15(4), 295-301
86. Sjostrom, B.; Kaplun, A.; Talmon, Y.; Cabane, B. Structures of nanoparticles prepared from oil-in-water emulsions. Pharm. Res., 1995, 12(1), 39-48
87. Shahgaldian, P.; Da Silva, E.; Coleman, A.W.; Rather, B.; Zaworotko, M.J. Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters. Int. J. Pharm., 2003, 253(1-2), 23-38
88. Hu, F.Q.; Yuan, H.; Zhang, H.H.; Fang, M. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int. J. Pharm., 2002, 239(1-2), 121-128
89. Trotta, M.; Debernardi, F.; Caputo, O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int. J. Pharm., 2003, 257(1-2), 153-160
90. Schubert, M.A.; Muller-Goymann, C.C. Solvent injection as a new approach for manufacturing lipid nanoparticles-evaluation of the method and process parameters. Eur. J. Pharm. Biopharm., 2003, 55(1), 125-131
91. Cortesi, R.; Esposito, E.; Luca, G.; Nastruzzi, C. Production of lipospheres as carriers for bioactive compounds. Biomaterials, 2002, 23(11), 2283-2294
92. Morel, S.; Terreno, E.; Ugazio, E.; Aime, S.; Gasco, M.R. NMR relaxometric investigations of solid lipid nanoparticles (SLN) containing gadolinium (III) complexes. Eur. J. Pharm. Biopharm., 1998, 45(2), 157-163
93. Heurtault, B.; Salunier, P.; Pech, B.; Proust, J.E.; Benoit, J.P. A novel phase inversion based process for the preparation of lipid nanocarriers. Pharm. Res., 2002, 19(6), 875-880
94. Charcosset, C.; El-Harati, A.; Fessi, H. Preparation of solid lipid nanoparticles using a membrane contactor. J. Control. Release, 2005, 108(1), 112-120
95. Bunjes, H.; Koch, M.H.; Westesen, K. Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J. Pharm. Sci., 2003, 92(7), 1509-1520
96. Gaba, B.; Fazil, M.; Ali, A.; Baboota, S.; Sahni, J.K.; Ali, J. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration. Drug Deliv., 2014, 1-10, Doi: 10.3109/10717544.2014.898110 (Epub ahead of print).
97. Lippacher, A.; Muller, R.H.; Mader, K. Semisolid SLN dispersions for topical application: influence of formulation and production parameters on viscoelastic properties. Eur. J. Pharm. Biopharm., 2002, 53(2), 155-160
98. Han, F.; Li, S.; Yin, R.; Liu, H.; Xu, L. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: nanostructured lipid carriers. Colloids Surf. A. Physicochem. Eng. Asp., 2008, 315, 210-216
99. Kovacevic, A.; Savic, S.; Vuleta, G; Müller, R.H.; Keck, C.M. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. Int. J. Pharm., 2011, 406(1-2), 163-172
100. Yuan, H.; Miao, J.; Du, Y.Z.; You, J.; Hu, F.Q.; Zeng, S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int. J. Pharm., 2008, 348(1-2), 137-145
101. Iqbal, M.A.; Md, S.; Sahni, J.K.; Baboota, S.; Dang, S.; Ali, J. Nanostructured lipid carriers system: recent advances in drug delivery. J. Drug Target., 2012, 20(10), 813-830
102. Charman, W.N.; Stella, V.J. Lymphatic transport of drugs. Boca Raton: CRC Press; 1992
103. Jores, K.; Mehnert, W.; Drechsler, M.; Bunjes, H.; Johann, C.; Mäder, K. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J. Control. Release, 2004, 95(2), 217-227
104. Saupe, A.; Wissing, S.A.; Lenk, A.; Schmidt, C.; Müller, R.H. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) -structural investigations on two different carrier systems. Biomed. Mater. Eng., 2005, 15(5), 393-402
105. Fang, J.Y.; Fang, C.L.; Liu, C.H.; Su, Y.H. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm., 2008, 70(2), 633-640
106. Hentschel, A.; Gramdorf, S.; Müller, R.H.; Kurz, T. Beta-caroteneloaded nanostructured lipid carriers. J. Food Sci., 2008, 73(2), 1-6
107. Pardeike, J.; Weber, S.; Haber, T.; Wagner, J.; Zarfl, H.P.; Plank, H.; Zimmer, A. Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int. J. Pharm., 2011, 419(1-2), 329-338
108. Muller, R.H.; Runge, S.A.; Ravelli, V.; Thunemann, A.F.; Mehnert, W.; Souto, E.B. Cyclosporine-loaded solid lipid nanoparticles (SLN®): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm., 2008, 68(3), 535-544
109. Muller, R.H.; Runge, S.; Ravelli, V.; Mehnert, W.; Thunemann, A.F.; Souto, E.B. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int. J. Pharm., 2006, 317(1), 82-89
110. Liu, D.H.; Liu, C.X.; Zou, W.W.; Zhang, N. Enhanced gastrointestinal absorption of N-3-O-toluyl-fluorouracil by cationic solid lipid nanoparticles. J. Nanopart. Res., 2010, 12(3), 975-984
111. Zhang, J.; Fan, Y.; Smith, E. Experimental design for the optimization of lipid nanoparticles. J. Pharm. Sci., 2009, 98(5), 1813-1819
112. Anton, N.; Benoit, J.P.; Saulnier, P. Design and production of nanoparticles formulated from nano-emulsion templates-a review. J. Control. Release, 2008, 128(3), 185-199
113. Souto, E.B.; Wissing, S.A.; Barbosa, C.M.; Müller, R.H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm., 2004, 278(1), 71-77
114. Saupe, A.; Gordon, K.C.; Rades, T. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy. Int. J. Pharm., 2006, 314(1), 56-62
115. Sahana, B.; Santra, K.; Basu, S.; Mukherjee, B. Development of biodegradable polymer-based tamoxifen citrate-loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in vitro evaluation. Int. J. Nanomedicine, 2010, 5, 621-630
116. Souto, E.B.; Mehnert, W.; Muller, R.H. Polymorphic behaviour of Compritol 888 ATO as bulk lipid and as SLN and NLC. J. Microencapsul., 2006, 23(4), 417-433
117. Estella-Hermoso de Mendoza, A.; Campanero, M.A.; Mollinedo, F.; Blanco-Prieto, M.J. Lipid nanomedicines for anticancer drug therapy. J. Biomed. Nanotechnol., 2009, 5(4), 323-343
118. Bunjes, H.; Steiniger, F.; Richter, W. Visualizing the structure of triglyceride nanoparticles in different crystal modifications. Langmuir, 2007, 23(7), 4005-4011
119. Estella-Hermoso de Mendoza, A.; Rayo, M.; Mollinedo, F.; Blanco-Prieto, M.J. Lipid nanoparticles for alkyl lysophospholipid edel-fosine encapsulation: development and in vitro characterization. Eur. J. Pharm. Biopharm., 2008, 68(2), 207-213
120. Muller, R.H.; Mader, K.; Gohla, S. Solid lipid NPs (SLN) for controlled drug delivery -a review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50(1), 161-77
121. Muller, R.H.; Radtke, M.; Wissing, S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm., 2002, 242(1-2), 121-128
122. Uprit, S.; Sahu, R.K.; Roy, A.; Pare, A. Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm. J., 2013, 21(4), 379-385
123. Jang, S.H.; Wientjes, M.G.; Lu, D.; Au, J.L. Drug delivery and transport to solid tumors. Pharm. Res., 2003, 20(9), 1337-1350
124. Pugh, C.W.; Ratcliffe, P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med., 2003, 9(6), 677-684
125. McDonald, D.M.; Choyke, P.L. Imaging of angiogenesis: from microscope to clinic. Nat. Med., 2003, 9(6), 713-725
126. Dvorak, H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol., 2002, 20(21), 4368-4380
127. Hodivala-Dilke, K.M.; Reynolds, A.R.; Reynolds, L.E. Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res., 2003, 314(1), 131-144
128. Hashizume, H.; Baluk, P.; Morikawa, S.; McLean, J.W.; Thurston, G.; Roberge, S.; Jain, R.K.; McDonald, D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol., 2000, 156(4), 1363-1380
129. Leu, A.J.; Berk, D.A.; Lymboussaki, A.; Alitalo, K.; Jain, R.K. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res., 2000, 60(16), 4324-4327
130. Netti, P.A.; Hamberg, L.M.; Babich, J.W.; Kierstead, D.; Graham, W.; Hunter, G. J.; Wolf, G.L.; Fischman, A.; Boucher, Y.; Jain, R.K. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc. Natl. Acad. Sci. USA., 1999, 96(6), 3137-3142
131. Sim, H.; Bibee, K.; Wickline, S.; Sept, D. Pharmacokinetic modeling of tumor bioluminescence implicates efflux, and not influx, as the bigger hurdle in cancer drug therapy. Cancer Res., 2011, 71(3), 686-692
132. Heldin, C.H.; Rubin, K.; Pietras, K.; Ostman, A. High interstitial fluid pressure -an obstacle in cancer therapy. Nat. Rev. Cancer, 2004, 4(10), 806-813
133. Primeau, A.J.; Rendon, A.; Hedley, D.; Lilge, L.; Tannock, I.F. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin. Cancer Res., 2005, 11, 8782-88
134. Biedler, J.L.; Riehm, H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res., 1970, 30(4), 1174-1184
135. Tredan, O.; Galmarini, C.M.; Patel, K.; Tannock, I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst., 2007, 99(19), 1441-1454
136. Riordan, J.R.; Deuchars, K.; Kartner, N.; Alon, N.; Trent, J.; Ling, V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature, 1985, 316(6031), 817-819
137. Ueda, K.; Cardarelli, C.; Gottesman, M.M.; Pastan, I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. U. S. A., 1987, 84(9), 3004-3008
138. Gouaze, V.; Yu, J.Y.; Bleicher, R.J.; Han, T.Y.; Liu, Y.Y.; Wang, H.; Gottesman, M.M.; Bitterman, A.; Giuliano, A.E.; Cabot, M.C. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol. Cancer Ther., 2004, 3(5), 633-639
139. Szakacs, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman, M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov., 2006, 5(3), 219-234
140. Gong, J.; Jaiswal, R.; Mathys, J.M.; Combes, V.; Grau, G.E.; Bebawy, M. Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat. Rev., 2012, 38(3), 226-234
141. Gottesman, M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med., 2002, 53, 615-627
142. Ak, Y.; Demirel, G.; Gulbas, Z. MDR1, MRP1 and LRP expression in patients with untreated acute leukaemia: correlation with 99mTc-MIBI bone marrow scintigraphy. Nucl. Med. Commun., 2007, 28(7), 541-546
143. Saraswathy, M.; Gong, S. Different strategies to overcome multidrug resistance in cancer. Biotechnol. Adv., 2013, 31(8), 1397-1407
144. Elbashir, S.M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001, 411(6836), 494-498
145. Hannon, G.J. RNA interference. Nature, 2002, 418(6894), 244-251
146. Milane L.; Ganesh S.; Shah S.; Duan Z.; Amiji M. Multi-modal strategies for overcoming tumor drug resistance: Hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. J. Control. Release, 2011, 155(2), 237-247
147. Zhang, S.; Zhao, B.; Jiang, H.; Wang, B.; Ma, B. Cationic lipids and polymers mediated vectors for delivery of siRNA. J. Control. Release, 2007, 123(1), 1-10
148. Chung, Y.L.; Troy, H.; Banerji, U.; Jackson, L.E.; Walton, M.I.; Stubbs, M.; Griffiths, J.R.; Judson, I.R.; Leach, M.O.; Workman, P.; Ronen, S.M. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J. Natl. Cancer Inst., 2003, 95(21), 1624-1633
149. Lin, X.; Gao, R.; Zhang, Y.; Qi, N.; Zhang, Y.; Zhang, K.; He, H.; Tang, X. Lipid nanoparticles for chemotherapeutic applications: strategies to improve anticancer efficacy. Expert Opin. Drug Deliv., 2012, 9(7), 767-781
150. Schimmel, K.J.; Richel, D.J.; van den Brink, R.B.; Guchelaar, H.J. Cardiotoxicity of cytotoxic drugs. Cancer Treat. Rev., 2004, 30(2), 181-191
151. Pazdur, R.; Kudelka, A.P.; Kavanagh, J.J.; Cohen, P.R.; Raber, M.N. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat. Rev., 1993, 19(4), 351-386
152. Selvamuthukumar, S.; Velmurugan, R. Nanostructured lipid carriers: A potential drug carrier for cancer chemotherapy. Lipids Health Dis., 2012, 11,159
153. Ewesuedo, R.B.; Ratain, M.J. In: Oncologic Therapeutics; Vokes, E.E.; Golomb, H.M. Eds.; New York: Springer, 2003, pp.19-66
154. Danhier, F.; Feron, O.; Preat, V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release, 2010, 148(2), 135-146
155. Subedi, R.K.; Kang, K.W.; Choi, H.K. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur. J. Pharm. Sci., 2009, 37(3-4), 508-513
156. Torchilin, V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev., 2011, 63(3), 131-135
157. Prabhakar, U.; Maeda, H.; Jain, R.K.; Sevick-Muraca, E.M.; Zamboni, W.; Farokhzad, O.C.; Barry, S.T.; Gabizon, A.; Grodzinski, P.; Blakey, D.C. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res., 2013, 73(8), 2412-2417
158. Mohanty, C.; Das, M.; Kanwar, J.R.; Sahoo, S.K. Receptor mediated tumor targeting: an emerging approach for cancer therapy. Curr. Drug Deliv., 2011, 8(1), 45-58
159. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul., 2001, 41, 189-207
160. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev., 2011, 63(3), 136-151
161. Hu, C.M.; Zhang, L. Therapeutic nanoparticles to combat cancer drug resistance. Curr. Drug Metab., 2009, 10(8), 836-841
162. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev., 2002, 54(5), 631-651
163. Gu, F.X.; Karnik, R.; Wang, A.Z.; Alexis, F.; Levy-Nissenbaum, E.; Hong, S.; Langer, R.S.; Farokhzad, O.C. Targeted nanoparticles for cancer therapy. Nanotoday, 2007, 2(3), 14-21
164. Steichen, S.D.; Caldorera-Moore, M.; Peppas, N.A. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur. J. Pharm. Sci., 2013, 48(3), 416-427
165. Wang, Y.; Zhang, H.; Hao, J.; Li, B.; Li, M.; Xiuwen, W. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect. Drug Deliv., 2015, 1-6, Doi:10.3109/10717544.2015.1055619 (Epub ahead of print)
166. Wang, Z.P.; Wu, J.B.; Chen, T.S.; Zhou, Q.; Wang, Y.F. In vitro and in vivo antitumor efficacy of berberine-nanostructured lipid carriers against H22 tumor. Proc. SPIE, 2015, 9324, 93240Y-1
167. Chen, Y.; Pan, L.; Jiang, M.; Li, D.; Jin, L. Nanostructured lipid carriers enhance the bioavailability and brain cancer inhibitory efficacy of curcumin both in vitro and in vivo. Drug Deliv., 2015, 1-10, Doi:10.3109/10717544.2015.1049719 (Epub ahead of print).
168. Tsai, M.J.; Wu, P.C.; Huang, Y.B.; Chang, J.S.; Lin, C.L.; Tsai, Y.H.; Fang, J.Y. Baicalein loaded in tocol nanostructured lipid car riers (tocol NLCs) for enhanced stability and brain targeting. Int. J. Pharm., 2012, 423(2), 461-470
169. Minko, T.; Rodriguez-Rodriguez, L.; Pozharov, V. Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Adv. Drug Deliv. Rev., 2013, 65(13-14), 1880-1895
170. Varshosaz, J.; Hassanzadeh, F.; Sadeghi, H.; Andalib, S. Synthesis of octadecylamine-retinoic acid conjugate for enhanced cytotoxic effects of 5-FU using LDL targeted nanostructured lipid carriers. Eur. J. Med. Chem., 2012, 54, 429-438
171. Bondi, M.L.; Azzolina, A.; Craparo, E.F.; Botto, C.; Amore, E.; Giammona, G.; Cervello, M. Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells. J. Nanobiotechnology, 2014, 12, 21, Doi: 10.1186/1477-3155-12-21
172. Moghimi, S.M.; Szebeni, J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res., 2003, 42(6), 463-478
173. Lim, S.B.; Banerjee, A.; Onyuksel, H. Improvement of drug safety by the use of lipid-based nanocarriers. J. Control. Release, 2012, 163(1), 34-45
174. Rudmann, D.G.; Alston, J.T.; Hanson, J.C.; Heidel S. High molecular weight polyethylene glycol cellular distribution and PEGassociated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins. Toxicol. Pathol., 2013, 41(7), 970-983
175. Gao, W.; Xiang, B.; Meng, T.T.; Liu, F.; Qi, X.R. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides. Biomaterials, 2013, 34(16), 4137-4149
176. Jia, L.; Shen, J.; Zhang, D.; Duan, C.; Liu, G.; Zheng, D.; Tian, X.; Liu, Y.; Zhang, Q. In vitro and in vivo evaluation of oridoninloaded long circulating nanostructured lipid carriers. Int. J. Biol. Macromol., 2012, 50(3), 523-529
177. Luan, J.; Zhang, D.; Hao, L.; Qi, L.; Liu, X.; Guo, H.; Li, C.; Guo, Y.; Li, T.; Zhang, Q.; Zhai, G. Preparation, characterization and pharmacokinetics of Amoitone B-loaded long circulating nanostructured lipid carriers. Colloids Surf. B. Biointerfaces, 2014, 114, 255-260
178. Wang, L.; Luo, Q.; Lin, T.; Li, R.; Zhu, T.; Zhou, K.; Ji, Z.; Song, J.; Jia, B.; Zhang, C.; Chen W.; Zhu, G. PEGylated nanostructured lipid carriers (PEG-NLC) as a novel drug delivery system for biochanin A. Drug Dev. Ind. Pharm., 2015, 41(7), 1204-1212
179. Zhao, X.; Zhao, Y.; Geng, L.; Li, X.; Wang, X.; Liu, Z.; Wang, D.; Bi, K.; Chen, X. Pharmacokinetics and tissue distribution of docetaxel by liquid chromatography-mass spectrometry: evaluation of folate receptor-targeting amphiphilic copolymer modified nanostructured lipid carrier. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2011, 879(31), 3721-3727
180. Yang, X.; Yi, C.; Luo, N.; Gong, C. Nanomedicine to overcome cancer multidrug resistance. Curr. Drug Metab., 2014, 15(6), 632-649
181. Zhang, X.G.; Miao, J.; Dai, Y.Q.; Du, Y.Z.; Yuan, H., Hu, F.Q. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int. J. Pharm., 2008, 361(1-2), 239-244
182. Mussi, S.V.; Sawant, R.; Perche, F.; Oliveira, M.C.; Azevedo, R.B.; Ferreira, L. A.M.; Torchilin, V.P. Novel nanostructured lipid carrier co-loaded with Doxorubicin and Docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr Cells. Pharm. Res., 2014, 31(8), 1882-1892
183. Zhou, L.; Chen, Y.; Zhang, Z.; He, J.; Du, M.; Wu, Q. Preparation of tripterine nanostructured lipid carriers and their absorption in rat intestine. Pharmazie, 2012, 67(4), 304-310
184. Chen, Y.; Yuan, L.; Zhou, L.; Zhang, Z.H.; Cao, W.; Wu, Q. Effect of cell-penetrating peptide-coated nanostructured lipid carriers on the oral absorption of tripterine. Int. J. Nanomedicine, 2012, 7, 4581-4591
185. Shete, H.; Chatterjee, S.; De, A.; Patravale, V. Long chain lipid based tamoxifen NLC. Part II: Pharmacokinetic, biodistribution and in vitro anticancer efficacy studies. Int. J. Pharm., 2013, 454(1), 584-592
186. Velmurugan, R.; Selvamuthukumar, S. In vivo antitumor activity of a novel orally bioavailable Ifosfamide nanostructured lipid carrier against Dalton’s ascitic lymphoma. J. Pharm. Innovation, 2014, 9(3), 203-211
187. Liu, D.; Liu, Z.; Wang, L.; Zhang, C.; Zhang, N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf. B. Biointerfaces, 2011, 85(2), 262-269
188. Liu, D.; Liu, F.; Liu, Z.; Wang, L.; Zhang, N. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Mol. Pharm., 2011, 8(6), 2291-2301
189. Yang, X.Y.; Li, Y.X.; Li, M.; Zhang, L.; Feng, L.X.; Zhang, N. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett., 2012, 334(2), 338-345
190. Chinsriwongkul, A.; Chareanputtakhun, P.; Ngawhirunpat, T.; Rojanarata, T.; Silaon, W.; Ruktanonchai, U.; Opanasopit, P. Nanostructured lipid carriers (NLC) for parenteral delivery of an anticancer drug. AAPS Pharm. Sci. Tech., 2012, 13(1), 150-158
191. Zhang, X.Y.; Qiao, H.; Ni, J.M.; Shi, Y.B.; Qiang, Y. Preparation of isoliquiritigenin-loaded nanostructured lipid carrier and the in vivo evaluation in tumor-bearing mice. Eur. J. Pharm. Sci., 2013, 49(3), 411-422
192. Rahman, H.S.; Rasedee, A.; Abdul, A.B.; Zeenathul, N.A.; Othman, H.H.; Yeap, S.K.; How, C.W.; Hafiza, W.A. Zerumboneloaded nanostructured lipid carrier induces G2/M cell cycle arrest and apoptosis via mitochondrial pathway in a human lymphoblastic leukemia cell line. Int. J. Nanomedicine, 2014, 9, 527-538
193. Qu, C.Y.; Zhou, M.; Chen, Y.; Chen, M.; Shen, F.; Xu, L.M. Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy. Int. J. Nanomedicine, 2015, 10, 3911-3920
194. Liu, Q.; Li, J.; Pu, G.; Zhang, F.; Liu, H.; Zhang, Y. Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy. Drug Deliv., 2015, 1-5, Doi:10.3109/10717544.2015.1031295 (Epub ahead of print).
195. Chen, J.; Chen, H.; Cui, S.; Xue, B.; Tian, J.; Achilefu, S.; Gu, Y. Glucosamine derivative modified nanostructured lipid carriers for targeted tumor delivery. J. Mater. Chem., 2012, 22(12), 5770-5783
196. Patlolla, R.R.; Chougule, M.; Patel, A.R.; Jackson, T.; Tata, P.N.; Singh, M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J. Control. Release, 2010, 144(2), 233-241
197. Taratula, O.; Kuzmov, A.; Shah, M.; Garbuzenko, O.B.; Minko, T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J. control. Release, 2013, 171(3), 349-357
198. Kaur, P.; Garg, T.; Rath, G.; Murthy, R.S.; Goyal, A.K. Development, optimization and evaluation of surfactant-based pulmonary nanolipid carrier system of paclitaxel for the management of drug resistance lung cancer using Box-Behnken design. Drug Deliv., 2014, 1-14, Doi:10.3109/10717544.2014.993486 (Epub ahead of print).
199. Chen, Y.; Zhou, L.; Yuan, L.; Zhang, Z.H.; Liu, X., Wu, Q. Formulation, characterization, and evaluation of in vitro skin permeation and in vivo pharmacodynamics of surface-charged tripterine-loaded nanostructured lipid carriers. Int. J. Nanomedicine, 2012, 7, 3023-3033
200. Madane, R.G.; Mahajan, H.S. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study. Drug Deliv., 2014, 1-9, Doi:10.3109/ 10717544.2014.975382 (Epub ahead of print).
201. Warner, S. Diagnostics plus therapy = theranostics. Scientist, 2004, 18, 38-39
202. Akhter, S.; Ahmad, I.; Ahmad, M. Z.; Ramazani, F.; Singh, A.; Rahman, Z.; Ahmad, F.J.; Storm, G.; Kok, R.J. Nanomedicines as cancer therapeutics: current status. Curr. Cancer Drug Targets, 2013, 13(4), 362-378
203. Chen, F.; Ehlerding, E.B.; Cai, W. Theranostic nanoparticles. J. Nucl. Med., 2014, 55, 1919-1922
204. Hsu, S.H.; Wen, C.J.; Al-Suwayeh, S.A.; Huang, Y.J.; Fang, J.Y. Formulation design and evaluation of quantum dot-loaded nanostructured lipid carriers for integrating bioimaging and anticancer therapy. Nanomedicine (Lond), 2013, 8(8), 1253-1269
205. Patel, A.R.; Chougule, M.B.; Lim, E.; Francis, K.P.; Safe, S.; Singh, M. Theranostic tumor homing nanocarriers for the treatment of lung cancer. Nanomedicine, 2014, 10(5), 1053-1063
206. Savla, R.; Garbuzenko, O.B.; Chen, S.; Rodriguez-Rodriguez, L.; Minko, T. Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapy. Pharm. Res., 2014, 31(12), 3487-3502
207. Xue, H.Y.; Wong, H.L. Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. Biomaterials, 2011, 32(10), 2662-2672
208. Han, Y.; Zhang, Y.; Li, D.; Chen, Y.; Sun, J.; Kong, F. Transferrinmodified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin. Int. J. Nanomedicine, 2014, 9, 4107-4016
209. Shao, Z.; Shao, J.; Tan, B.; Guan, S.; Liu, Z.; Zhao, Z.; He, F.; Zhao, J. Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. Int. J. Nanomedicine, 2015, 10, 1223-1233
210. Chen, Z.; Lai, X.; Song, S.; Zhu, X.; Zhu, J. Nanostructured lipid carriers based temozolomide and gene co-encapsulated nanomedicine for gliomatosis cerebri combination therapy. Drug Deliv., 2015, 1-5, Doi:10.3109/10717544.2015.1038857 (Epub ahead of print).
211. Han, Y.; Li, Y.; Zhang, P.; Sun, J.; Li, X.; Sun, X.; Kong, F. Nanostructured lipid carriers as novel drug delivery system for lung cancer gene therapy. Pharm. Dev. Technol., 2015, 1-5, Doi:10.3109/10837450.2014.996900 (Epub ahead of print).